Meeting
2024 ASCO Genitourinary Cancers Symposium
The role of cytoreductive nephrectomy (CN) in the immune checkpoint inhibitor (ICI) era of metastatic renal cell carcinoma (mRCC): A systematic review and individual patient data (IPD) meta-analysis of 2319 patients.
Authors
Dimitrios Makrakis
Department of Medicine, NYC Health + Hospitals/Jacobi, Albert Einstein College of Medicine, Bronx, NY
Dimitrios Makrakis , Pavlos Msaouel , Jose A. Karam , Stepan M. Esagian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 425)
DOI
10.1200/JCO.2024.42.4_suppl.425
Abstract #
425
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of cytoreductive nephrectomy (CN) on survival in metastatic renal cell cancer (mRCC) treated with immune checkpoint inhibitors (ICI).
First Author: Stuthi Perimbeti
Poster
2021 Genitourinary Cancers Symposium
Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: A systematic review and individual patient data meta-analysis.
First Author: Stepan M. Esagian
Poster
2020 Genitourinary Cancers Symposium
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
First Author: Joseph Miccio
Poster
2024 ASCO Genitourinary Cancers Symposium
Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.
First Author: Renee Maria Saliby